Helicobacter pylori enzymes and structures (H. pylori targets)

Helicobacter pylori is a microaerophilic, Gram-negative bacterium that colonizes the human gastric mucosa, serving as the primary etiological agent for chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma (StatPearls, 2023). The enzymes and structures of H. pylori are essential for its survival in the acidic gastric lumen and its subsequent pathogenesis. Urease is a hallmark enzyme that neutralizes stomach acid by producing ammonia, which is vital for initial colonization (Nature Reviews Disease Primers, 2017). Structural components like flagella provide the motility necessary to penetrate the gastric mucus, while adhesins such as BabA and SabA facilitate persistent attachment to epithelial cells (World Journal of Gastroenterology, 2014). Virulence factors, including the Vacuolating cytotoxin A (VacA) and Cytotoxin-associated gene A (CagA), are translocated into host cells to modulate immune responses and induce tissue damage (Frontiers in Microbiology, 2020). Pharmacological intervention typically involves a combination of antibiotics—such as amoxicillin, clarithromycin, and metronidazole—that target bacterial cell wall synthesis, protein translation, and DNA integrity (Mayo Clinic, 2023). The increasing prevalence of antibiotic resistance against these targets poses a significant challenge to successful eradication and necessitates the development of novel therapeutic strategies (Lancet Infectious Diseases, 2018).

Other names

Helicobacter pylori proteomeH. pylori virulence factorsH. pylori metabolic enzymesGastric Helicobacter targets

Drugs targeting H. pylori enzymes and structures act through several distinct pathways: amoxicillin inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs); clarithromycin and tetracycline inhibit protein synthesis by binding to the 50S and 30S ribosomal subunits, respectively; metronidazole and tinidazole are prodrugs that, when reduced, cause DNA strand breakage; and levofloxacin inhibits DNA gyrase and topoisomerase IV, preventing DNA replication (NIH/PubChem, 2023; StatPearls, 2023).